Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025

Aug 18, 2015, 09:00 ET from Visiongain

LONDON, August 18, 2015 /PRNewswire/ --

Explore the Potentials of New Drug 

Kinase Inhibitors - Benefit Your Influence Now by Discovering Their Sales Potentials
Do you want to find sales potentials of protein kinase inhibitors for treating cancer? You can now explore the latest research and development and market predictions. Our new study shows you R&D trends, results, opportunities and multilevel revenue forecasts.

Visiongain's report shows you what is possible for drugs using protein kinase inhibition. That way you assess the future of cancer treatment. Find progress in that rising industry and market, discovering expected progress and sales, including the influence of new products.

Avoid missing out. With our research and analysis you assess trends, companies and products, benefiting your reputation for technological and commercial insight. That way discover what is possible from 2015.

Progress of that industry - discover prospects for those novel anti-cancer medicines
Are you tired of struggles to find business data on cancer therapy? Instead benefit your work through our new study, seeing how to help your data searches, analyses, decisions, proposals and presentations.

With our new study you explore the future of those therapies. Read on, then, to investigate that industry and see how high its future sales could go.

Forecasts and other information showing technical, clinical and commercial possibilities
The new study gives you sales predictions to 2025 at overall world market, submarket, company, product and national level. See what the future holds for those advances in cancer therapy. For kinase-inhibiting drugs you investigate where demand and money lie.

In our work you receive 83 tables, 73 charts and two interviews with other authorities. Besides giving revenue predictions, our new analysis shows recent results, growth rates and market shares.

Although no single study covers everything, the following sections show how our new investigation benefits your work.

To see a report overview please email Sara Peerun on

Forecasting of that world market and its segments - what's possible for those treatments?
What is the potential of that biomedical industry? What are the secrets of its progress? Discover in our report overall world revenue to 2025 for inhibition of protein kinases.

There you also find individual revenue predictions to 2025 for eight submarkets at world level:
• Bcr-Abl tyrosine-kinase inhibitors (TKI)
• Angiogenesis inhibitors
• EGFR inhibitors
• mTOR inhibitors
• BRAF and MEK inhibitors
• Other kinase inhibitors
• Pipeline drugs
• Generics and other agents.

Our work investigates products, uses and revenues past and future. That way you assess outlooks for expansion in trade, seeing where potential sales increases can appear, helping you stay ahead.

The new study also explores competition. There you investigate activities of developers, producers and marketers of kinase inhibiting medicines, understanding their challenges, trends and outlooks. You also examine revenues by product.

Product forecasts - investigate sales potentials of existing and expected therapies
How will top marketed and expected kinase treatments perform to 2025 at world level?

Our new analysis shows you individual revenue predictions for 28 marketed products, including these drugs:
• Glivec (imatinib)
• Sprycel (dasatinib)
• Tasigna (nilotinib)
• Tarceva (erlotinib)
• Nexavar (sorafenib)
• Sutent (sunitinib)
• Afinitor (everolimus)
• Imbruvica (ibrutinib).

That study includes profiles for 23 medicines in development and revenue forecasts for seven leading drug candidates, including these agents:
• Venetoclax (ABT-199)
• Duvelisib (IPI-145)
• Buparlisib (BKM120)
• Cobimetinib (GDC-0973).

With our analysis you discover sales potentials for leading brands of those enzyme inhibitors. Discover what is possible, from 2015, for transforming that industry and market.

Also our survey splits its overall world market into geographical revenue predictions.

National markets for those drug sales - what does the future hold?
Advances in biotechnology and healthcare expand use of anti-cancer drugs, including protein kinase inhibitors. Our study shows you prospects for those sales in developed and developing regions.

There see individual revenue forecasting to 2025 for 11 countries:
United States (US)
Germany, France, United Kingdom (UK), Italy and Spain, also with overall EU prediction
Brazil, Russia, India and China (BRIC nations).

With our analysis you investigate countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

Also how do events, challenges and advances in technology affect that industry and market? Our report shows you, discussing progress, policies and trends.

Forces affecting developers, producers and sellers of those pharmaceuticals
Our study explains issues, events and R&D affecting that oncology from 2015, including these advances:
• Cyclin-dependent kinase 4/6 and ALK inhibitors in development
• Bruton's tyrosine kinase and PI3K agents for the future
• MEK and BRAF inhibition - prospects for new treatments.

Also explore these trends and influences, among others, assessing their impact:
• Stratification of patients and cancer genomics for more-personalised medicine
• Ageing populations and rising cancer prevalence increasing demand
• Generic competition - challenges for original branded drugs
• Biologics - including monoclonal antibodies (mAbs)
• Combination therapies - potential for improvements in treating patients.

Our study explains that industry's strengths, weaknesses, opportunities and threats. It also explores social, technological, economic and political questions. Those methods let you analyse that market, its progress and potential, discovering from 2015 what is possible.

Kinase inhibitors for treating cancer - what revenues are likely by 2019?
What happens next? From 2015, protein kinase inhibitors for treating cancer patients hold great potential for investments, technological advances and sales. Visiongain predicts the world market for those products will grow to $31.2bn in 2019, with further expansion to 2025.

In particular our study explores activities and potentials of nine companies, forecasting revenues to 2025 for seven firms:
• Novartis
• Pfizer
• Roche
• Bristol-Myers Squibb
• Bayer
• AstraZeneca
• Gilead Sciences.

Our survey also shows interviews by visiongain with other authorities on anti-cancer kinase inhibitors:
• Infinity Pharmaceuticals
• LYMMCARE (Lymphoma and Myeloma Center Amsterdam).

From 2015, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations' potentials.

Ways Kinase Inhibitors for Cancer Treatment: World Industry Analysis, R&D and Market Forecasts 2015-2025 helps
In these seven main ways, our new investigation benefits your work:
• Kinase inhibitors revenue to 2025 - discover the sales potential of that cancer treatments market
• 8 main submarkets' revenues to 2025 - explore that industry's segments at world level, finding the most lucrative and fast growing product groups
• 35 drugs' and 7 leading companies' revenues to 2025 - find sales predictions for top medicines and their producers, seeing how they can compete and succeed
• 11 national markets' forecasts to 2025 - investigate leading countries in the Americas, Europe and Asia for revenues from those drugs
• Activities of established, rising and emerging companies - assess organisations' products, capabilities, advances and outlooks, also getting opinions from interviews
• R&D reviews and forecasts - explore technological, clinical and commercial opportunities and outlooks, helping you succeed
• Analysis of what stimulates and restrains that pharmaceuticals market - assess challenges and strengths, helping you compete and gain advantages.

To see a report overview please email Sara Peerun on

That study, by visiongain's in-house analysts in the UK, gives knowledge with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.

Information there found nowhere else, benefiting your research, analyses and plans
Our report gives independent analysis. With it you receive business intelligence found only in our work, seeing where commercial prospects are most rewarding.

With that investigation you are less likely to fall behind in information or miss opportunity. Discover now how you can help your research, analysis, decisions, presentations and proposals, reducing wasted time and benefiting your authority.

Our new analysis is for everyone assessing the present and future of cancer treatment. That way you explore results, trends, opportunities and sales predictions. So stay ahead in knowledge - please request our report here now.

To request an exec summary of this report please email Sara Peerun at or call Tel: +44 (0) 20 7336 6100

Or click on:

Organisations Mentioned in the Report 

ARIAD Pharmaceuticals
Array BioPharma
ASCO (American Society of Clinical Oncology)
Avilion Group
Bayer Healthcare
Boehringer Ingelheim BioXcellence
Brazilian Unified Health System (SUS)
Bristol-Myers Squibb
CDC (Centers for Disease Control and Prevention)
Chia Tai Tianging Pharma
China Food and Drug Administration
CHMP (Committee for Medicinal Products for Human Use)
Chugai Pharmaceuticals
Clovis Oncology
Consumer Healthcare Venture
Daiichi Sankyo Group
DIPP (Department of Industrial Policy and Promotion)
Eli Lilly
EMA (European Medicines Agency)
European Commission
European Organisation for Research and Treatment and Cancer (EORTC)
FDA (US Food and Drug Administration)
Genentech (subsidiary of Roche)
Gilead Sciences
GSK Consumer Healthcare
Infinity Pharmaceuticals
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG)
Janssen Pharmaceutical (subsidiary of J&J)
Jiangsu Hansoh Pharma
Johnson & Johnson
Laborers Health and Welfare Trust Fund for Northern California
Merck KGaA
MHLW (Ministry of Health, Labour, and Welfare, Japan)
National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP)
NCCN (National Comprehensive Cancer Network)
NHS (National Health Service, UK)
NICE (the National Institute for Health and Care Excellence, UK)
ONO Pharmaceuticals
Onyx (part of Amgen)
ORP (Oncology Research Program)
Orphan Biovitrum (Sobi)
OSI Pharmaceuticals
Otsuka Pharmaceutical
Peregrine Pharmaceuticals
Plexxikon (Daiichi Sankyo Group)
Puma Biotechnology
Sun Pharma
Teva Pharmaceutical Industries
UCSF (University of California, San Francisco)
United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund

To see a report overview please email Sara Peerun on

To request an exec summary of this report please email Sara Peerun at or call Tel: +44-(0)-20-7336-6100

Or click on

SOURCE Visiongain